

IAP10 Rec'd PCT/R 29 NOV 2005

#4

STEFAN J. KLAUBER*
DAVID A. JACKSON
ROGER M. RATHBUN*
LAWRENCE D. MANDEL*
J. DAVID SMITH*

*BAR OTHER THAN N.J.
* COUNSEL

PATENT AGENTS

CHRISTINE E. DIETZEL, PH.D.
VERONICA M. MALLON, PH.D.
SARAH J. FASHENA, PH.D.

KLAUBER & JACKSON L.L.C.

ATTORNEYS AT LAW
CONTINENTAL PLAZA
411 HACKENSACK AVENUE
HACKENSACK, NEW JERSEY 07601

PATENT, TRADEMARK AND
COPYRIGHT CAUSES

(201) 487-5800

FACSIMILE:

(201) 343-1684

website:

www.kjiplaw.com

Writer's direct e-mail:

David.Jackson@kjiplaw.com

November 29, 2005

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Re: International Patent Application No. PCT/GB03/05651

Now U.S. Serial No. **10/540,645**

Applicant(s) : Peter Knox, Michele O'Sullivan; Heike Lentfer
Title : PIPERIDINYL-THIAZOLE CARBOXYLIC
ACID DERIVATIVES AS ANGIOGENESIS
INHIBITORS

Filing Date : June 24, 2005

Docket No. : 1396-1-011PCT/US

EXPRESS MAIL "MAILING LABEL NO." : EV 708028057 US

DATE OF DEPOSIT : NOVEMBER 29, 2005

12/02/2005 ATRAN1
01 FC:2617

00000097 10540645

^{65.00 pp}
SUBMISSION OF MISSING REQUIREMENTS UNDER
35 U.S.C. 371 IN THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)

Dear Sir:

Responsive to the Notification of Missing Requirements under 35 U.S.C. 371 in the U.S.
Designated/Elected Office, copy enclosed, Applicants submit herewith the following:

1. A combined Declaration and Power of Attorney making reference to the above-identified Application, and in compliance with 37 CFR 1.497 (a) and (b).
2. A check in the amount of \$65.00, representing the Surcharge under 37 CFR 1.492(h).
3. A Response to Request for Sequence Listing Under 37 CFR 1.821(e) contained within Notification of Missing Requirements Under 35 USC 371 in the United States Designated/Elected Office (DO/EO/US).

MAIL STOP PCT
COMMISSIONER FOR PATENTS


November 29, 2005

Page - 2 -

Docket No.: 1396-1-011PCT/US

Applicants hereby authorize that any charges in addition to the above authorized that relate to the filing and processing of the present Application in accordance with 37 CFR 1.16 and 1.17 may be charged to Deposit Account No. 11-1153. A duplicate copy of this letter is provided for this purpose.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'David A. Jackson', is written over a horizontal line.

DAVID A. JACKSON
Attorney for Applicant(s)
Registration No. 26,742

DAJ/kg
Enclosures

Rec'd PCT/PTO 29 NOV 2005

#4

Attorney Docket No.: 1396-1-011PCT/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Peter Knox et al. EXAMINER : Unknown
SERIAL NO. : 10/540,645 ART UNIT : Unknown
FILED : June 24, 2005
FOR : PIPERIDINYL-THIAZOLE CARBOXYLIC ACID DERIVATIVES
AS ANGIOGENESIS INHIBITORS

EXPRESS MAIL "MAILING LABEL NO." : EV 708028057 US

DATE OF DEPOSIT : NOVEMBER 29, 2005

RESPONSE TO REQUEST FOR SEQUENCE LISTING UNDER 37 CFR §1.821(e)
CONTAINED WITHIN NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 USC
371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


This is in response to the request for the submission of a Sequence Listing with respect to the above-identified application, contained within the Notification of Missing Requirements, having a date of mailing of November 23, 2005. For purposes of reference to the following response, a further copy of the said Notification is attached hereto. It should be understood that the primary copy that is to be submitted with the reply to the Notification is also enclosed with the rest of the documents submitted in compliance with the requirement for completeness in the response to the said requirements.

Applicants submit that the request for a sequence listing is in error in this application, in as much as the application contains no specific disclosure of particular nucleic acids or amino acids as is generally requisite for the submission of a sequence listing. Rather, and upon a careful review of the present application, it will be clear that the present application is directed explicitly to organic compounds and thus does not require the submission of a sequence listing. In fact, nowhere in the present application are references contained or even referred to indirectly, that would embrace either nucleic acid materials or proteins or amino acid materials and that would consequently, call for the submission of a sequence listing.

On the basis of the above and upon a careful review of the application, applicants believe that the said requirement should be withdrawn and hereby request a formal written confirmation and withdrawal thereof so as to complete the record herein.

Such early and favorable action on applicants' request is believed to be in order, and is courteously solicited.

Respectfully submitted,



DAVID A. JACKSON
Attorney for Applicants
Registration No. 26,742

KLAUBER & JACKSON LLC
411 HACKENSACK AVE., 4TH FLOOR
HACKENSACK, NJ 07601
PHONE: 201-487-5800

DATE: NOVEMBER 29, 2005



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/540,645	Peter Knox	1396-1-011PCT/US

INTERNATIONAL APPLICATION NO.

PCT/GB03/05651

I.A. FILING DATE

12/24/2003

PRIORITY DATE

12/24/2002

23565

KLAUBER & JACKSON
 411 HACKENSACK AVENUE
 HACKENSACK, NJ 07601

NOV 28 2005

CONFIRMATION NO. 8879

371 FORMALITIES LETTER



OC000000017508923

Date Mailed: 11/23/2005

DUED: 1/23/06
 DDD: 5/23/06

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Indication of Small Entity Status
- Copy of the International Application filed on 06/24/2005
- Copy of the International Search Report filed on 06/24/2005
- Copy of IPE Report filed on 06/24/2005
- Preliminary Amendments filed on 06/24/2005
- Oath or Declaration filed on 06/24/2005
- Small Entity Statement filed on 06/24/2005
- Request for Immediate Examination filed on 06/24/2005
- U.S. Basic National Fees filed on 06/24/2005
- Priority Documents filed on 06/24/2005
- Specification filed on 06/24/2005
- Claims filed on 06/24/2005
- Abstracts filed on 06/24/2005

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
 - is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath

DOCKETED ON

✓

or declaration) as set forth in 37 CFR 1.492(h) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

Total additional fees required for this application is **\$65** for a Small Entity:

- **\$65 Surcharge.**
- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- **For Rules Interpretation, call (571) 272-0951**
- **For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov**

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

VONDA M WALLACE

Telephone: (703) 308-9140 EXT 225

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/540,645	PCT/GB03/05651	1396-1-011PCT/US

FORM PCT/DO/EO/905 (371 Formalities Notice)